Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome

Genetic Testing and Molecular Biomarkers

Volumn 20, Issue 7, 2016, Pages 341-345

  Albitar, Ferras ^a   Ma, Wanlong ^a   Diep, Kevin ^a   De Dios, Ivan ^a   Agersborg, Sally ^a   Thangavelu, Maya ^a   Brodie, Steve ^a   Albitar, Maher ^a  

^a NeoGenomics California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CELL FREE DNA; DNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASXL1 GENE; CBL GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; ETV6 GENE; EZH2 GENE; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; IDH1 GENE; IDH2 GENE; INTERMETHOD COMPARISON; MALE; MOLECULAR DIAGNOSIS; MYELODYSPLASTIC SYNDROME; NEXT GENERATION SEQUENCING; ONCOGENE N RAS; RUNX1 GENE; SANGER SEQUENCING; SF3B1 GENE; SRSF2 GENE; TET2 GENE; TP53 GENE; U2AF1 GENE; ZRSR2 GENE; BLOOD; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROCEDURES; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DNA; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; SENSITIVITY AND SPECIFICITY;

EID: 84978849218     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2015.0278     Document Type: Article

References (22)

1. Ahmed M, Giles F, Joe Y, et al. (2003) Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma. Eur J Haematol 71:174-178.
2. Albitar M, Manshouri T, Shen Y, et al. (2002) Myelodysplastic syndrome is not merely preleukemia. Blood 100:791-798.
3. Albitar M, Zhou W, Giles F (2004) Myelodysplastic syndrome: from morphology to biology. Curr Hematol Rep 3:159-164.
4. Bejar R, Abdel-Wahab O (2013) The importance of subclonal genetic events in MDS. Blood 122:3550-3551.
5. Bejar R, Stevenson K, Abdel-Wahab O, et al. (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506.
6. Chen K, Meric-Bernstam F, Zhao H, et al. (2015) Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem 61:544-553.
7. Giles FJ, Albitar M (2007) Plasma-based testing as a new paradigm for clinical testing in hematologic diseases. Expert Rev Mol Diagn 7:615-623.
8. Greenberg PL (2012) Molecular and genetic features of myelodysplastic syndromes. Int J Lab Hematol 34:215-222.
9. Haferlach T, Nagata Y, Grossmann V, et al. (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241-247.
10. Itzykson R, Kosmider O, Fenaux P (2013) Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. Best Pract Res Clin Haematol 26:355-364.
11. Jilani I, Estey E, Manshuri T, et al. (2003) Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia 17:114-119.
12. Kerbauy DB, Deeg HJ (2007) Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 35:1739-1746.
13. Kitamura T, Inoue D, Okochi-Watanabe N, et al. (2014) The molecular basis of myeloid malignancies. Proc Jpn Acad Ser B Phys Biol Sci 90:89-404.
14. Ma W, Kantarjian H, Zhang X, et al. (2008) Higher detection rate of JAK2 mutation using plasma. Blood 111:3906-3907.
15. Ma W, Kantarjian H, Zhang X, et al. (2009) Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomarkers 5:51-58.
16. Ma W, Tseng R, Gorre M, et al. (2007) Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica 92: 170-175.
17. Malcovati L, Papaemmanuil E, Ambaglio I, et al. (2014) Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood 124:1513-1521.
18. Raza A, Galili N (2012) The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 12:849-859.
19. Rogers A, Joe Y, Manshouri T, et al. (2004) Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood 103:2799-2801.
20. Steensma DP (2015) Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 90:969-983.
21. Thol F, Kade S, Schlarmann C, et al. (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119:3578-3584.
22. Yeh CH, Tseng R, Albitar M (2009) Plasma-based detection of clonality in lymphoid malignancies. Eur J Haematol 82: 450-453.